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Inflammation and NF-κB in Alzheimer’s
Disease and Diabetes
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Abstract. Inflammatory processes are a hallmark of many chronic diseases including Alzheimer’s disease and diabetes mellitus.
Fairly recent statistical evidence indicating that type 2 diabetes increases the risk of developing Alzheimer’s disease has led
to investigations of the potential common processes that could explain this relation. Here, we review the literature on how
inflammation and the inducible nuclear factor NF-κB might be involved in both diabetes mellitus and Alzheimer’s disease and
whether these factors can link both diseases.
Keywords: Alzheimer’s disease, inflammation, insulin, insulin-degrading enzyme, nuclear factor-κB, receptor for advanced
glycation endproducts (RAGE), tumor necrosis factor, type 2 diabetes mellitus
INTRODUCTION
Since the beginning of the 20th century, there has
been a continuous knowledge-based improvement in
healthcare in most industrialized societies. As a result,
people in these affluent societies live longer, which has
led to an increase in prevalence of age-related neurode-
generative diseases such as stroke and dementia. Dia-
betes mellitus (DM) has long been known as a risk fac-
tor for all vascular diseases, including vascular demen-
tia. Indeed, the epidemiological relationship was re-
cently explored in several large-scale studies. Further-
more, population-based cohort studies, such as the Rot-
terdam study, have shown that patients with type 2 DM
(T2DM) are approximately twice as likely to develop
Alzheimer’s disease (AD), independent of vascular fac-
tors [1,2]. The fact that neurodegenerative diseases are
often associated with metabolic diseases such as DM
suggests an underlying or aggravating metabolic basis.
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Here, we will provide a survey of the multiple levels of
interactions between metabolic diseases and AD, and
vice versa, and the particular role of inflammatory pro-
cesses in these interactions. Although inflammation
can be considered at least initially as a reaction of tis-
sue against various stressors, chronic inflammation can
be seen as part of the pathological process. A number
of studies have shown that inflammatory signaling in
peripheral organs can influence central nervous system
(CNS) functions, while reversely the CNS can have
profound effects on peripheral functions. To partially
illustrate these multiple mechanisms of interaction, we
focus in this review on the transcription factor family
NF-κB, which plays a major role in the initiation of
the innate and adaptive immune response. This review
concentrates on the role of inflammation and NF-κB in
DM and AD.
INFLAMMATION AND DIABETES MELLITUS
Involvement of inflammation in DM was first rec-
ognized more than a century ago, when Ebstein ob-
served that the anti-inflammatory drug sodium salicy-
late dramatically reduced glucosuria in DM patients [3].
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Fig. 1. Inflammation as a central event in the pathogenesis of AD and DM. Aging, diet, genetic risk or other unknown factors can directly
or indirectly lead to the pathological changes underlying both diseases. However, chronic inflammation may amplify the pathogenic processes
through sustained NF-κB activation and elevated cytokine levels, which eventually lead to insulin resistance and DM, or result in increased
amyloid-β (Aβ) production and microglia activation, which are symptomatic of AD.
Following the classification of type-1 (i.e., insulin-
dependent) and type-2 (i.e., non-insulin-dependent)
DM, other, more distinctive inflammatory processes
were thought to play a role, especially in the etiology
of T2DM. T2DM, which is characterized by an insuf-
ficient release of insulin from pancreatic beta-cells to
overcome insulin resistance in target tissues, is usually
associated with increased levels of markers and medi-
ators of inflammation and acute-phase reactants such
as fibrinogen, C-reactive protein (CRP), interleukin-6
(IL-6), plasminogen activator inhibitor-1 (PAI-1), sial-
ic acid, and white cell count. An additional connection
between inflammation, obesity, and T2DM in which
obese patients exhibited an elevated level of cytokines
that caused hepatic insulin resistance has been found
(Fig. 1) [4]. The fact that T2DM is a comorbidity of
increased visceral adiposity has stimulated interest in
the role of adipose tissue as a mediator of inflamma-
tory processes underlying the development of T2DM.
Indeed, the proinflammatory cytokine tumor necrosis
factor-alpha (TNF-α), which is produced and secret-
ed by adipose tissue, is found to induce insulin resis-
tance through local and potentially systemic effects on
metabolism [5,6]. Subsequent to the idea that fat tis-
sue is a site for the production of cytokines and other
bioactive substances, the concept quickly developed be-
yond TNF-α to include leptin, IL-6, resistin, monocyte
chemoattractant protein-1 (MCP-1), angiotensinogen,
retinol-binding protein-4, serum amyloid A (SAA),
and others [7–9]. Furthermore, TNF-α, IL-6, MCP-1,
visfatin, and PAI-1 are highly expressed in activated
macrophages and/or other peripheral tissue, as well as
in the brain. At this moment, it is not known if cy-
tokines are produced by the adipocytes themselves or
by monocytes which have invaded adipose tissue [10].
This knowledge gap has engendered an intense debate.
INFLAMMATION IN ALZHEIMER’S DISEASE
The idea that neuroinflammatory factors play a role
in the etiology of AD dates back to 1910, when Fischer
I. Granic et al. / NF-κB in Alzheimer’s Disease and Diabetes 811
reported that the extracellular deposition of a “foreign”
substance in the cerebral cortex induced both a local
inflammatory response and the formation of cerebral
plaques [11]. Due to the inadequate detection meth-
ods at the time, it was not possible to identify the pre-
cise structure of this “foreign” substance or to establish
the ultimate proof for the involvement of inflammato-
ry molecules. Today, however, it is well known that
the major component of the “foreign” substances is the
amyloid-β protein (Aβ). The Aβ peptide is the result
of a proteolytic cleavage of the amyloid-β protein pre-
cursor (AβPP). This precursor protein can be processed
in two different ways: via amyloidogenic- or via non-
amyloidogenic-processing. Non-amyloidogenic pro-
cessing involves cleavage within the Aβ sequence by
α-secretase, which prevents the formation of Aβ. On
the other hand, the amyloidogenic pathway is medi-
ated by sequential cleavage of AβPP by β-secretase
(BACE) and γ-secretase, which results in the genera-
tion of Aβ1−40 and Aβ1−42 species [12,13].
This Aβ peptide plays a central role in the neuroin-
flammation hypothesis of AD, which states that Aβ ac-
cumulation results in increased levels of inflammatory
molecules (e.g., cytokines, chemokines, complement
proteins) produced by chronically activated glia. This
leads to neuronal damage, which in turn induces fur-
ther glial activation, and results in a detrimental cycle
of neuroinflammation and neurodegeneration [14].
TNF-α is one of the most prominent pro-inflamma-
tory cytokines significantly increased in AD and it plays
a central role in initiating and regulating the cytokine
cascade during inflammatory responses [15,16]. For
example, TNF-α increases the expression of adhesion
molecules on the vascular endothelium, which allows
leukocytes and immune cells to infiltrate areas of tissue
damage and infection [17]. TNF-α exerts its biolog-
ical functions via two distinct receptors: TNF recep-
tor 1 (TNF-R1) and TNF receptor 2 (TNF-R2). The
55 kDa TNF-R1 (p55/60) is a membrane-receptor and
is expressed in most tissues where it can be stimulated
by both the membrane-bound and the soluble form of
TNF-α. The functions of TNF-R1 range from induc-
ing apoptosis and differentiation to NF-κB-mediated
cell survival [18]. Similar to TNF-R1, also the 75 kDa
TNF-R2 (p75/80) is a membrane-receptor, but because
of its low affinity to soluble TNF-α, it can be fully acti-
vated only by membrane-bound TNF-α. The functions
of TNF-R2 are as complex as those of TNF-R1 and are
still not revealed in all its detail. It is known that the
action of the TNF receptors is strongly dependent on
the cell type. For instance, TNF-R2 is able to amplify
apoptotic signals from TNF-R1 in cancer cell lines [19]
but has also been reported to mediate neuroprotection,
as shown in a model for glutamate-induced excitotoxi-
city [20]. TNF-R2 exerts its protective properties when
pre-stimulated with TNF-α, which suggests a neuro-
protective role in the CNS [20,21]. In AD patients,
TNF-R1 levels are increased [15], whereas TNF-R2
levels are decreased [22].
Recently, it was demonstrated that overexpression
of TNF-R1 promotes Aβ-induced neuronal death in
an AβPP overexpressing mouse model for AD [23].
In contrast, mice lacking TNF-R1 have a decreased
amyloid plaque burden, lower expression of BACE, and
improved learning abilities compared to controls [24].
Interestingly, the stimulation of both TNF receptors can
lead to the activation of NF-κB, which has binding sites
in the promoter regions of both the AβPP and the BACE
gene [25]. Mutations in the NF-κB promotor region
of BACE lead to a significant decrease in promotor
activity of TNF-α activated glia cells or Aβ exposed
neurons, which indicates an activating role of NF-κB in
BACE expression [26]. In this way, NF-κB activation
can lead to increased AβPP expression and enhanced
amyloidogenic AβPP processing. Elevated AβPP and
BACE expression will ultimately lead to increased Aβ
production, which can in turn activate glia cells and
enhance neuroinflammatory processes.
INFLAMMATION AND THE NF-κB FAMILY
Inflammation is defined as the local response to tis-
sue injury [27], and NF-κB is considered as a prima-
ry regulator of inflammatory processes. The NF-κB
family of transcription factors is an evolutionarily con-
served signaling system that plays an important role in
many biological processes in addition to inflammation.
NF-κB was first described in B cells, but it was later
shown to exist in an inactive cytosolic form in all cell
types, including the nervous system [28]. NF-κB also
plays a central role in the initiation and amplification of
inflammation by responding to proinflammatory stim-
uli such as TNF-α or interleukin-1 (IL-1) [29–31]. As
illustrated in Fig. 1, aberrant regulation of NF-κB leads
to the development of many pathological states espe-
cially those involving acute inflammation such as AD
and DM [32,33].
However, NF-κB is not the only transcription factor
activated under inflammatory conditions. Activation of
other transcription factors such as PPARγ and STAT-1
have also been implicated in AD [34,35].
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INVOLVEMENT OF NF-κB IN DIABETES
MELLITUS AND ALZHEIMER’S DISEASE
The NF-κB family
Different members of the NF-κB family have been
identified in mammalian cells: p65 (RelA), RelB, c-
Rel, p50/p105 (NF-κB1), and p52/p100 (NF-κB2).
NF-κB1 and NF-κB2 are synthesized as large precur-
sors, p105 and p100,which are post-translationally pro-
cessed to the DNA-binding subunits p50 and p52, re-
spectively. All members of the NF-κB family have an
N-terminal 300 amino acid Rel homology domain that
allows DNA binding, dimerization, and nuclear local-
ization in common [36]. NF-κB proteins are present
in unstimulated cells as homo- or heterodimers bound
to the inhibitor of the kappa B (IκB) family of proteins
IκBα, IκBβ, IκBγ, IκBδ, IκBNS, Bcl-3, and the p100
and p105 precursor proteins. Association with IκB
prevents the nuclear translocation of the NF-κB:IκB
complex.
Currently, two NF-κB activation pathways have been
identified (Fig. 2). Classical/canonical NF-κB activ-
ity is stimulated by proinflammatory cytokines, such
as TNF-α and IL-1, as well as by pathogen-associated
molecular patterns (PAMPs). The binding of these lig-
ands to their respective receptors, i.e., the TNF-R, Toll-
like receptor (TLR) and the interleukin-1 receptor (IL-
1R) superfamilies, causes activation of various cellular
signaling pathways such as the protein kinase C (PKC),
mitogen-activated protein (MAP) kinase kinase kinase-
1 (MEKK1), and also the PKB/Akt signaling pathway,
all of which have the potential to phosphorylate the IκB
kinase (IKK) complex. IKK consists of two catalyt-
ic subunits (IKKα and IKKβ) and a regulatory sub-
unit (IKKγ). In the canonical pathway, the activated
IKK complex predominantly acts through IKKβ in an
IKKγ-dependent manner to catalyze the phosphoryla-
tion of IκBs. Upon phosphorylation, IκB releases NF-
κB, allowing it to translocate to the nucleus and to ini-
tiate gene transcription (Fig. 2a). The most commonly
released NF-κB dimer in this pathway is the p50-RelA
dimer [37].
The alternative/non-canonical activation pathway is
activated by certain members of the TNF cytokine fam-
ily but not by TNF-α itself and is strictly dependent on
IKKα [38]. The target for IKKα homodimers in this
pathway is NF-κB2/p100 (Fig. 2b).
Recent results strongly suggest that the canonical
and non-canonical pathways to NF-κB activation have
distinct regulatory functions. Whereas the classical
pathway was found to be mostly involved in innate
immunity and maintaining survival of immune cells,
the alternative pathway is an important player in adap-
tive immunity and the development and organization of
secondary lymphoid organs and B-cell maturation [39].
NF-κB regulates several promoters containing vari-
ations in a highly divergent consensus DNA-binding
sequence. Variations in the DNA-binding site appear to
confer regulatory specificity for NF-κB family mem-
bers by two general mechanisms. The sequence of the
site can determine which coactivators form productive
interactions with the bound NF-κB dimer [40]. This
mode of specificity occurs independently of any inher-
ent difference in DNA binding by distinct dimers. A
second mechanism conferring specificity of transcrip-
tional regulation involves differential affinity of NF-
κB dimer combinations for different DNA-binding se-
quences sites. NF-κB signaling can be switched off
through multiple mechanisms, including the new syn-
thesis of IκBα protein.
The activation and nuclear translocation of classical
NF-κB dimers (mostly p50–RelA) is associated with
increased transcription of genes encoding chemokines,
cytokines, and adhesion molecules [intercellular ad-
hesion molecule 1 (ICAM-1), vascular cell adhesion
molecule-1 (VCAM-1), and endothelial–leukocyte ad-
hesion molecule 1 (ELAM)], all of which are factors
that produce secondary inflammatory mediators [41].
NF-κB regulates proliferation and apoptosis by control-
ling the expression of the cellular inhibitors of apopto-
sis (cIAP1, cIAP2, and XIAP) [42,43], the TNF recep-
tor associated factors (TRAF1 and TRAF2) [43], the
bcl-2 homologue A1/Bfl-1, and IEX-IL [44]. Interest-
ingly, NF-κB activation can thus lead to the expression
of the same cytokines that can also regulate its activity,
such as IL-1β and TNF-α. This results in a positive
auto-regulatory loop contributing to the amplification
of the inflammatory response and the persistence of
chronic inflammation at local sites.
NF-κB and diabetes
After Ebstein’s discovery [3] and a somewhat later
investigation by Williamson [45], the role of salicy-
lates in the treatment DM were long forgotten, in part
because of the fact that the well-established effects of
low doses of salicylates to block cyclo-oxygenase en-
zyme activation of prostaglandin synthesis [46] were
far below the concentration of salicylates necessary to
induce effects on glucose homeostasis [47]. High dos-
es of salicylates, however, had been found to inhibit
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Fig. 2. The activation of NF-κB transcription factors occurs through two main pathways: a) the canonical and b) the non-canonical NF-κB
activation pathway. During canonical signaling upstream mediators activate the IκB kinase (IKK) complex to phosphorylate inhibitory IκB
proteins, leading to their ubiquitination and degradation. NF-κB dimers are then free to bind to DNA and to activate gene transcription.
Alternative, non-canonical NF-κB signaling is mediated by NF-κB Inducing Kinase (NIK), which induces the partial proteolytical degradation
of p100 to p52. RelB, together with p52, translocates to the nucleus and transactivates their target genes.
NF-κB [47], and its upstream component, IκB kinase-
β (IKK-β). Cai and colleagues [48] were able to in-
duce a T2DM phenotype in mice by selectively ex-
pressing IKKβ in hepatocytes, characterized by hyper-
glycemia and insulin resistance. A definitive role for
the IKKβ/NF-κB in glucose homeostasis was substan-
tiated when targeted deletion of IKKβ in obese and
diabetic mice completely reversed insulin resistance in
these animals [49–51].
Evidence in support of a critical role of NF-κB in the
pathogenesis in early stages of DM can be described
as threefold (regarded as activators, effectors, and as
modulators of the NF-κB activity).
First, in DM, the increase in NF-κB activators
promotes vascular complications. Thus far, at least
four molecular mechanisms have been implicated in
glucose-mediated vascular diseases. These mecha-
nisms include: glucose-mediated activation of PKC
isoforms; increased formation of glucose-derived ad-
vanced glycation endproducts (AGEs); the aldose-
reductase (AR) pathway; and increased formation of re-
active oxygen species (ROS). Furthermore, all of these
pathways have been demonstrated to increase NF-κB
activity. Hyperglycemia leads to the activation of dif-
ferent isoforms of PKC in accordance with tissue types,
thus determining the specific kind of DM-induced or-
gan damage [52]. Activation of the AR pathway is
necessary for high-glucose-induced TNF-α synthesis
and release. In DM, high-glucose mediated TNF-α
release has been shown to cause cardiovascular com-
plications [53]. Although targeting PKC isoforms and
AR products has proven to be a difficult and chal-
lenging task, targeting glucose-derived AGE- receptor
for advanced glycation endproducts (RAGE) products
became more feasible with the availability of RAGE
knockout mice and a competitive decoy for AGEs, sol-
uble RAGE (sRAGE). Diabetic RAGE overexpressing
transgenic mice showed exacerbated neuropathy, while
inhibition of AGE formation prevented these vascular
cell derangements [54,55]. On the other hand, it was
found that RAGE knockout mice were resistant to DM-
induced neuropathy. In human DM patients, NF-κB
activation is a time consuming process and is associ-
ated with increased transcription of the p65 subunit of
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NF-κB [56]. These findings were paralleled by in vitro
studies, in which it was shown that RAGE-expressing
cells induced sustained translocation of p50/p65 sub-
units of NF-κB from the cytoplasm into the nucle-
us. RAGE ligands induce NF-κB activation by initial
degradation of IκB proteins, followed by new synthe-
sis of the p65 subunit of NF-κB, although IκBα and
IκBβ are also generated. These findings indicate an
important function of de novo synthesized p65 subunit
in prevailing the NF-κB auto-inhibitory effects, thus in-
ducing a sustained NF-κB activation in hyperglycemic
conditions [56]. Several reports have shown that IKKβ,
which is responsible for the activation of NF-κB, was
also increased in insulin-resistant cells [49,51].
The importance of IKKβ in insulin resistance was
provided by data accumulated from IKKβ (+/−) het-
erozygous mice. Whereas IKKβ (−/−) homozygous
mice died in embryonic stages due to massive apoptosis
in the liver, IKKβ (+/−) heterozygous mice were re-
ported to exhibit a stronger insulin sensitivity compared
with their wild type littermates [49].
Second, inhibition of NF-κB effectors, such as
iNOS or ICAM proteins mediates beneficial effects re-
ducing DM-induced degeneration of retinal capillar-
ies [57]. In retinas of mice exhibiting streptozotocin-
induced DM, the concentrations of NO, of iNOS, the
nitration of proteins and leukostasis were significantly
increased when compared with non-diabetic mice [58].
Interestingly, in diabetic iNOS−/− mice not all of
the above-mentioned abnormalities were detected. In
addition, retinas from stretozotocin-induced DM mice
were significantly thinner than from non-diabetic con-
trol mice, whereas no retinal defects were observed in
diabetic iNOS−/− mice. Administration of the iNOS
specific inhibitor, N(G)-nitro-L-arginine methyl ester,
reduced DM-mediated leukostatis within retinal ves-
sels and blood-retinal barrier permeability [59]. These
studies showed that iNOS enzymes play a crucial role
in the pathogenesis of vascular lesions detected in early
stages of diabetic retinopathy [58,59].
Third, compounds known to inhibit the NF-κB path-
way also inhibit the development of the DM retinopa-
thy or neuropathy. In addition to the augmented ox-
idative stress-mediated cellular damage, T2DM pa-
tients usually present defects of cellular antioxidant de-
fense mechanisms, such as the glutathione redox sys-
tem, vitamin C-vitamin E cycle, and the α-lipoic acid
(LA)/dihydrolipoic acid (DHLA) redox pair [60]. An-
tioxidants inhibit the activation of NF-κB and the de-
velopment of inflammatory responses in several tissues,
including retinas of diabetic animals [61]. Consistent
with these findings, treatment with antioxidants signifi-
cantly suppressed the NF-κB activity and reduced plas-
ma markers for lipid oxidation [62]. LA treatment of
diabetic neuropathy restored the LA pool, increased the
insulin sensitivity [63], raised intracellular glutathione
levels [64], prevented glycation of serum albumin [65]
and reduced the oxidative stress-mediated NF-κB acti-
vation [62].
NF-κB in Alzheimer’s disease
NF-κB activation as a central event of inflammation
is a common feature of many neurodegenerative dis-
eases such as Huntington, Parkinson, stroke, and par-
ticularly of AD. In the brain of AD patients, activated
NF-κB was found predominantly in neurons and glial
cells in Aβ plaque surrounding areas [32,66–68]. The
reactive astrocytes in close proximity to the Aβ plaques
produce inflammatory cytokines, including IL-1β and
TNF-α, and iNOS, which generates free radicals such
as NO, that can be neurotoxic [69,70]. Several studies
have shown that Aβ and/or a secreted form of AβPP
induce an upregulation of NF-κB activity. Some non-
steroidal anti-inflammatory drugs (NSAIDs) have a di-
rect effect on NF-κB activity, which eventually results
in decreased AβPP processing. Flurbiprofen and in-
domethacin, which target NF-κB, have been shown to
effectively reduce the amyloid load in vitro and al-
so in AβPP transgenic mice [71,72]. The activation
of NF-κB leads to the expression of a large variety
of pro-inflammatory molecules such as cytokines and
chemokines, which could be in part responsible for the
neurotoxicity seen in AD. However, there are also re-
ports that certain cytokines, e.g., TNF-α, may trigger
NF-κB activation, which seems to be neuroprotective
against Aβ toxicity in cultured neurons [73,74].
Both pathological hallmarks of AD (Aβ and hyper-
phosphorylated tau) are capable of inducing NF-κB ac-
tivation via various mechanisms. One common mech-
anism is the activation of the AGE/RAGE signaling
pathway. Aβ and tau can undergo a non-enzymatic
glycation and form AGEs. These AGEs bind to so-
called RAGEs and can trigger NF-κB dependent gene
transcription. Furthermore, glycation of Aβ enhances
its aggregation in vitro [75], and glycated tau, in addi-
tion to hyperphosphorylation, appears to enhance the
formation of paired helical filaments (PHFs) [76,77].
In addition, AGEs have been reported to generate reac-
tive oxygen intermediates, leading to the activation of
cytokines including IL-1β and TNF-α, which in turn
induce the translocation of NF-κB to the nucleus [78].
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The recently discovered prolyl isomerase protein
Pin1, which accelerates the trans to cis or cis to trans
isomerization of target proteins, is apparently a ‘key
player’ in the pathogenesis of AD [79,80]. Pin1 has
been shown to bind to both AβPP and phosphorylated
tau, where it stabilizes the non-pathogenic conforma-
tions of both proteins. In AD, Pin1 levels are compro-
mised, leading to increased Aβ formation and reduced
tau de-phosphorylation. In addition, Pin1 might have a
role in neuronal apoptosis of AD-affected cells as well,
either indirectly, via depletion in the levels or aberrant
function of Pin1 (resulting from oxidation, phospho-
rylation or mutations) or directly, via association with
specific signaling proteins such as NF-κB.
During TNF-α treatment, Pin1 binds to the phos-
phorylated p65/Rel subunit on Thr 254 [81], enhanc-
ing NF-κB DNA binding and transactivation activi-
ty. Pin1 binding to p65/Rel inhibits p65 binding to
IκBα, which prevents p65/Rel nuclear export and its
subsequent ubiquitin mediated degradation. This leads
to enhanced nuclear accumulation, protein stability,
and transcriptional activity of NF-κB towards its target
genes, which in turn promotes neuronal survival [81].
Furthermore, a single mutation in p65/Rel abolish-
es Pin1 binding and destabilizes the protein in HeLa
and 293 cells. The source of destabilization has been
found to be enhanced ubiquitin mediated proteasomal
degradation [81]. Ryo and colleagues [81] suggest that
Pin1 stabilizes p65 and prevents its proteasomal degra-
dation, probably by isomerizing the Thr254-Pro motif
towards a more stable conformation, possibly indicat-
ing that in neurons in which NF-κB is induced, Pin1
might mediates neuronal survival by stabilizing NF-κB,
resulting in the transcription of its pro-survival target
genes. In addition, Pin1 has also been shown to bind
to these anti-apoptotic NF-κB target genes, possibly
stimulating survival downstream of NF-κB signaling
as well [82]. Thus, depletion of Pin1 could accelerate
neuronal cell death in AD patients. Since stabilization
of the p65/Rel subunit of NF-κB by Pin1 no longer
takes place, it will ultimately lead to a downregula-
tion of anti-apoptotic genes and, ultimately, to cellular
death.
MECHANISMS RELATING TYPE-2 DIABETES
MELLITUS AND ALZHEIMER’S DISEASE
Since the Rotterdam study and other studies linked
DM with an increased risk to develop AD, researchers
worldwide have searched for the causal mechanisms
underlying this relationship. Because the NF-κB path-
way plays a major role in the etiology of both diseases,
it seems reasonable to assume that mechanisms caus-
ing disturbances in this pathway are at the core of the
relationship (Fig. 3). A number of issues relevant to
this possibility need to be addressed.
First, in addition to their role in inflammation and
immune responses, neurons and their neighboring glial
cells also employ the NF-κB pathway for distinctive
functions ranging from the development to the coordi-
nation of cellular responses to injury of the nervous sys-
tem, and to brain-specific processes such as the synap-
tic signaling that underlies learning and memory. Inter-
estingly, electrical activity within neurons and synap-
tic transmission between neurons are potent stimuli for
NF-κB activation, and such neuronal activity may ac-
count for the relatively high constitutive activity of NF-
κB in brain tissue compared with other tissues [28]. As
in other organs, NF-κB influences the expression of a
complex array of genes in the nervous system, and, in
general, these genes serve important functions in cellu-
lar responses to injury and in neuronal plasticity. In the
nervous system, the cell type and the duration of NF-
κB activation appears to be a determining factor for the
output of NF-κB in neurodegenerative diseases such as
AD. NF-κB activation in neurons has been shown to
promote the survival and plasticity of these neurons.
On the other hand, NF-κB activation in glial cells may
play a major role in inflammatory processes that can
damage and kill neurons. Indeed, in some cases, the
NF-κB and the NF-κB responsive genes may serve du-
al functions. In neuronal cells, sustained activation
of NF-κB has been shown to induce neuroprotection
via PI3-kinase-PKB/Akt pathway activation [20]. Fur-
thermore, NF-κB cellular survival functions underlie
cytokine-inducedneuroprotective mechanisms, includ-
ing transforming growth factor-β1 (TGF-β1) and TNF-
α. Although transient activation of NF-κB in activat-
ed glial cells is beneficial for defense processes, ei-
ther chronic activation or overactivation may exacer-
bate neuronal diseases as seen in AD [83].
The second issue relates to the use of substrates for
metabolic purposes. Although the brain preferential-
ly utilizes glucose as the main substrate, ketone bod-
ies may replace glucose as the major energy source.
The liver is the main source for elevated ketones in the
circulation (e.g., in starvation or hypoglycemia), but
glial cells are also suitable to engage in ketone body
production via stimulation of AMP-activated protein
kinase (AMPK), a highly conserved stress-activated
kinase [84,85]. Sustained glucoprivation and hypox-
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ia, however, may cause neurons to release glutamate,
which in turn leads to chronic activation of the NF-
κB pathway in glia cells and their pro-inflammatory
actions.
The third issue relates to the fact that glial cells re-
quire insulin for glucose uptake (i.e., which is compara-
ble to peripheral tissue), whereas neuronal glucose up-
take is independent of insulin [86]. Thus, in the case of
insulin resistance, which underlies T2DM, this would
result in a limitation of glucose uptake in glial cells but
not in neurons. In fact, in the case of T2DM, neurons
often evidence elevated levels of glucose, which may
cause direct deleterious effects via the RAGE path-
way [87]. A reduction in glucose availability at the
level of glial cells might be expected to cause aug-
mented ketone body production and the chronic activa-
tion of the NF-κB pathway with the resulting inflam-
matory assaults on neuronal tissue, a scenario which
is somewhat comparable to the recent discussion by
Erol [88]. Here, we suggest a more central role for
the NF-κB pathway than has been put forward previ-
ously. Whether this scenario can explain the causality,
however, is still under investigation. Moroz and col-
leagues recently found that mice chronically subject-
ed to a high-fat diet displayed all the characteristics of
peripheral and central insulin resistance, but signs of
AD were only marginally observed [89]. Future ex-
periments must address species differences (e.g., the
variation of cholesterol metabolism in mice and in hu-
mans [90]), timing and lifespan or aging [91], and en-
vironmental challenges (e.g., psychological stress), of
all which could act as additional factors interacting in
the causal link between T2DM and AD. One particu-
larly interesting permissive mechanism linking insulin
and Aβ, which plays a central role in development of
both diseases, is the insulin-degrading enzyme (IDE).
In addition to defining a key role for IDE in both Aβ
and insulin metabolism in vivo, selective deletion of the
IDE gene recapitulates some of the hallmark pheno-
typic characteristics of AD and T2DM, namely chronic
elevation of cerebral Aβ, as in AD, and hyperinsuline-
mia and glucose intolerance, as in T2DM [92]. The
state of chronic inflammation has great influence on the
metabolism of Aβ and insulin. For example, in AD
chronic inflammation and augmented NF-κB, activa-
tion leads eventually to elevated Aβ levels, activation
of glia cells, and increased cytokine release. Further-
more, pro-inflammatory cytokines can directly reduce
the expression of IDE [93], which would compromise
the clearance of Aβ and promote its aggregation. In
T2DM, elevated levels of pro-inflammatory cytokines
such as TNF-α are known to induce insulin resistance
in peripheral tissues by reducing insulin receptor sub-
strate (IRS-1) phosphorylation [94] (Fig. 3).
Perez and colleagues [95] reported that the IDE activ-
ity may be reduced in AD patients compared to controls.
IDE levels are reduced in diabetic AβPP transgenic
mice that have increased cerebral Aβ levels compared
to non-diabetic AβPP transgenic controls [96]. Clinical
studies show that IDE levels are decreased in the hip-
pocampi of AD patients who have the apolipoprotein
ε4 gene [97]. In this context, it is interesting to note that
hippocampal volume is reduced in AD patients several
years before any symptoms can be detected [98].
A recent paper showed that impaired insulin signal-
ing can also lead to tau hyperphosphorylation in an ani-
mal model for DM [99]. Insulin and insulin-like growth
factor-1 stimulation reduces tau phosphorylation and
promotes tau binding to microtubules. These effects of
insulin and insulin-like growth factor-1 are mediated
through inhibition of glycogen-synthase kinase-3 via
the phosphatidylinositol 3-kinase/protein kinase B sig-
naling pathway [100]. It is known that insulin and the
Aβ protein compete for binding to the insulin recep-
tor [101]. Aβ co-immunoprecipitates with the insulin
receptor and interferes with the autophosphorylation
of the insulin receptor induced by insulin that affects
downstream targets such as Erk/MAPK, CaMKII and
PKB/Akt [102,103]. Insulin resistance or hypoinsuli-
naemia cause elevated glucose levels which in turn
leads to increases in AGEs. As the RAGE activates
NF-κB, it is conceivable that such an inflammatory
precondition might increase the risk for the onset of
AD.
All of these mechanisms reflect the variety of links
between T2DM and AD and how this linkage might
lead to pre-conditions favoring the development of AD.
However, it is also conceivable that central signal mech-
anisms preceding the phase of clinical symptoms of
AD might also aggravate or favor T2DM.
CONCLUSIONS AND FUTURE
PERSPECTIVES
It is clear from the reviewed literature that inflam-
matory processes are playing essential roles in the eti-
ology of T2DM and AD. Aberrant regulation of the in-
flammatory pathway involving NF-κB, which includes
TNF-α dependent (canonical) and TNF-α independent
(non-canonical) mechanisms, directly underlies insulin
resistance in peripheral tissue as well as in astrocytes
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Fig. 3. Schematic representation of molecular pathways linking the pathogenesis of T2DM and AD. Conditions such as oxidative stress,
pro-inflammatory cytokines, activated RAGE, and insulin receptor stimulation can directly or indirectly, lead to sustained activation of NF-κB
(p50/p65). Upon phosphorylation, IκB becomes degraded and NF-κB can translocate into the nucleus to initiate NF-κB dependent gene
transcription (e.g., TNF-α, IL-6, IL-1β, iNOS, COX-2, BACE, AβPP). Aβ monomers and oligomers activate RAGE, whereas insulin and the
Aβ protein compete for binding to the insulin receptor. Pro-inflammatory cytokines can directly reduce the expression of IDE, which would
compromise the clearance of Aβ and insulin in the extracellular domain. Aβ, amyloid-β peptide; AβPP, amyloid-β protein precursor; AKT,
protein kinase B/AKT; BACE, β-secretase; γ-sec, γ-secretase; IDE, insulin degrading enzyme; IKK, inhibitor of κB kinase; IκB, inhibitor of κB;
IRE, insulin response element; LRP-1, Low density lipoprotein-related protein 1; NEP, neprilysine; PI3-K, phosphoinositide-3 kinase; RAGE,
receptor for advanced glycation end products; ROS, reactive oxygen species; TNF-α, tumor necrosis factor-α; TNF-R, TNF receptor; Dashed
arrow: indirect effect; Full arrow: direct effect. +, positive stimulation; −, inhibitory effect.
in the brain. Since insulin resistance in the periph-
ery can lead to glucose intolerance, neuronal inflam-
matory processes triggering (or triggered by) the NF-
κB pathway may be propagated even further via stim-
ulation of the AGE/RAGE signaling pathway. There-
fore, it might be expected that alleviating symptoms of
T2DM may be an effective way to treat AD. Indeed,
recent clinical trials with the insulin sensitizer rosigli-
tazone, i.e., an agonist for the peroxisome proliferator-
activated receptor γ (PPARγ), whose biological ac-
tions are to regulate glucose and lipid metabolism and
suppress inflammatory gene expression, have shown a
significant improvement in memory and cognition in
AD patients [104]. The currently used multi-target-
directed ligand (MTDLs), usually including a mix of
inhibitors of acetylcholinesterase (AChE) and of mono-
amine oxidase (MAO) [105] may be complemented
with ligands (NSAIDs, PPARγ agonists) that improve
metabolic functions of neurons and microglia, in order
to delay or prevent deterioration of AD.
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